Molecular properties of cannabis-like analgesics identified

30 January 2017

Patients who have suffered tissue damage as a result of inflammatory diseases may benefit from analgesics which, at the molecular level, resemble the active substance in cannabis.

The main adverse effect of this substance is that it makes patients ‘high’, so the pharmaceutical industry is eagerly seeking synthetic alternatives. A team led by Dr Mario van der Stelt (of Leiden University) is conducting an extensive comparison – involving no fewer than 36 different tests – of the molecular pharmacological properties of commonly used cannabis-like reference substances. This joint study by academic and industrial groups was published in early January, in Nature Communications. One of the researchers’ findings was that, while the reference compounds tested all act on the same receptor, they each activate different molecular pathways.

The study was partly funded by an ECHO-STIP grant from the Netherlands Organisation for Scientific Research (NWO).
You can find further details about ECHO grants here .

Article in

Leiden Institute of Chemistry





Source: NWO